SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Bolt Biotherapeutics, Inc. Investors.

NEW YORK, May 16, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors in Bolt Biotherapeutics, Inc. (“Bolt” or the “Company”) (NASDAQ: BOLT). Such investors are encouraged to contact Danielle Peyton at (email protected) or 646-581-9980, extension 7980.

The investigation concerns whether Bolt and certain of its officers and/or directors engaged in securities transactions Fraud or other unlawful business practices.

(Click here for information about joining the class action lawsuit)

At May 14, 2024Bolt announced in a press release that the company was “ceasing further development of trastuzumab imbotolimod (BDC-1001),” Bolt’s lead product, “and will reduce the workforce by approximately 50%.” Following Bolt’s announcement, several analysts downgraded the company’s stock.

On this news, Bolt’s share price fell $00.49 per share or more than 37.12% to close $00.83 per share May 15, 2024.

Pomerantz LLP, with offices in new York, Chicago, Los Angeles, London, ParisAnd Tel Aviv, is considered one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the deceased Abraham L. PomerantzPomerantz, known as the dean of the class action bar, pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of securities victims Fraud, breaches of fiduciary duty and corporate misconduct. The company has sought numerous millions of dollars in damages on behalf of the class plaintiffs. See www.pomlaw.com.

Lawyer advertising. Previous results do not guarantee similar results.

CONTACT:
Danielle Peyton
Pomerantz LLP
(email protected)
646-581-9980 ext 7980

SOURCE Pomerantz LLP